Ignite Creation Date:
2024-05-06 @ 3:20 AM
Last Modification Date:
2024-10-26 @ 11:32 AM
Study NCT ID:
NCT02268448
Status:
COMPLETED
Last Update Posted:
2023-01-26
First Post:
2014-10-09
Brief Title:
Treatment of Chronic Itch in Atopic Dermatitis Eczema Nerve Function
Sponsor:
University of Minnesota
Organization:
University of Minnesota
Study Overview
Official Title:
Treatment of Chronic Itch in Atopic Dermatitis With Oral Clonidine and Oral Naltrexone Nerve Function
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety and efficacy of oral clonidine in subjects with symptomatic atopic dermatitis and to assess the safety and efficacy of oral naltrexone in subjects with symptomatic atopic dermatitis
Detailed Description:
This study will serve as a pilot study to determine the efficacy and safety of two novel oral agents clonidine naltrexone in the treatment of chronic non-experimentally induced itch in atopic dermatitis In this study eight subjects with symptomatic atopic dermatitis will be recruited and treated with either oral clonidine four subjects or oral naltrexone four subjects Disease burden will be evaluated before and after 4 weeks of treatment through reporting of subjective symptomatology via surveysquestionnaire neurometer study and clinical assessment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None